Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands

Journal of Medical Economics

Volumn 16, Issue 3, 2013, Pages 342-348

  Van Nooten, Floortje ^a   Stern, Sean ^a   Braunstahl, Gert Jan ^b   Thompson, Chris ^a   Groot, Martijn ^c   Brown, Ruth E ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b SINT FRANCISCUS GASTHUIS   (Netherlands)

^c Novartis Pharma BV   (Netherlands)

Author keywords

Allergic asthma; Cost effectiveness; Observational study; Omalizumab

Indexed keywords

OMALIZUMAB;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; REGISTRIES; YOUNG ADULT;

EID: 84873900286     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2012.756398     Document Type: Article

References (19)

1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
2. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004; 59:709-17
3. Braunstahl GJ, Leo J, Thirlwell J, et al. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin 2011;27:761-7
4. Lloyd A, Turk F, Leighton T, et al. Psychometric evaluation of global evaluation of treatment effectiveness: a tool to assess patients with moderate-to-severe allergic asthma. J Med Econ 2007;10:285-96
5. Brown R, Turk F, Dale P, et al. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62:149-53
6. Dewilde S, Turk F, Tambour M, et al. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin 2006;22:1765-76
7. College voor zorgverzekeringen (CVZ). Guidelines for pharmacoeconomic research, updated version. Diemen, The Netherlands: College voor zorgverzekeringen, 2006. http://www.cvz.nl/binaries/content/documents/ cvzinternet/en/documents/procedures/guidelines-pharmacoeconomic-research.pdf. Accessed August 1, 2011
8. Centraal Bureau voor de Statistiek. Centraal Bureau voor de Statistiek [web page]. http://www.cbs.nl/nl-NL/menu/home/default.htm. Accessed December 14, 2010.
9. Watson L, Turk F, James P, et al. Factors associated with mortality after an asthma admission: a national United Kingdom database analysis. Respir Med 2007;101:1659-64
10. Nederlandse Zorgautoriteit (NZA). Zoekprogramma DBC bedragen en overige bedragen medisch specialistische zorg door of vanwege de zorginstelling. Utrecht, The Netherlands: Nederlandse Zorgautoriteit (NZA), 2010. http://ctg.bit-ic.nl/Nzatarieven/top.do. Accessed December 20, 2010
11. Hakkaart-van Roijen L, Tan SS, Bouwmans CCA. Handleiding voor kostenon-derzoek: Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg (Geactualiseerde versie 2010). Diemen, The Netherlands: College voor Zorgverzekeringen, 2010. http://www.cvz.nl/binaries/content/ documents/cvzinternet/nl/documenten/rubriekzorgpakket/cfh/handleiding- kostenonderzoek-2010.pdf. Accessed February 18, 2011
12. Price Index. 2010. http://www.nza.nl/regelgeving/prijsindexcijfers/. Accessed December 14, 2010.
13. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-42
14. Lamers LM, Stalmeier PF, McDonnell J, et al. [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned Tijdschr Geneeskd 2005;149:1574-8
15. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J 2007;16:22-7
16. Lowhagen O, Ekstrom L, Holmberg S, et al. Experience of an emergency mobile asthma treatment programme. Resuscitation 1997;35:243-7
17. Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011;43:45-53
18. Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011;180:637-41
19. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Cape Town, South Africa: Global Initiative for Asthma (GINA), 2011. http://www.ginasthma.org/guidelines-gina-report-global-strategy- for-asthma.html. Accessed August 1, 2011